Localized microbubble cavitation-based antivascular therapy for improving HCC treatment response to radiotherapy. (28th December 2017)

• Record Type: Journal Article
• Authors: Daecher, Annemarie; Stanczak, Maria; Liu, Ji-Bin; Zhang, Jie; Du, Shisuo; Forsberg, Flemming; Leeper, Dennis B.; Eisenbrey, John R.
• Is Part Of: Cancer letters. Volume 411(2018)
• Page Start: 100
• Page End: 105
• Publication Date: 2017-12-28
• Subjects: Hepatocellular carcinoma -- Ultrasound contrast agent -- Ultrasound triggered microbubble destruction -- Antivascular therapy -- Radiotherapy; CEUS Contrast Enhanced Ultrasound -- HCC Hepatocellular Carcinoma -- UTMD Ultrasound Triggered Microbubble Destruction; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2017.09.037
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide and the fastest growing malignancy in the United States. With a 5-year survival rate below 12%, effective therapies for HCC are needed. Current treatments for HCC include microwave and radiofrequency ablation, high intensity focused ultrasound, liver transplant, surgical resection, and localized embolizations. However, each of these approaches has some limitation, making it imperative to develop improved methods for sensitizing tumors prior to therapy. We hypothesized that the use of ultrasound-triggered microbubble destruction (UTMD), which sensitizes tumors to radiotherapy by inducing vascular endothelial cell apoptosis, will selectively sensitize malignant tissue to radiotherapy and improve outcomes. To test this, 18 nude rats were inoculated in the right liver lobe with Hu7.5 HCC cells and after tumor formation, received 5 Gy radiotherapy, UTMD, or UTMD prior to radiotherapy. Compared to radiotherapy alone, there was a 170% reduction in tumor growth 7 days post treatment and a 3.2X improvement in median survival time when radiotherapy was combined with UTMD. These results indicate that UTMD is an effective adjunct when combined with radiotherapy to treat HCC. Highlights: Microbubble cavitation results in a reduction in HCC tumor vascularity. UTMD before radiation therapy improves tumor control in an orthotopic model of HCC. UTMD showed no effects on overall liver function tests compared to control groups. Vascular disruption does not increase tumor hypoxia within the treatment window.